Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234622 | 0.99 | HDAC3 (0.57) | HDAC3HDAC8ALDH1A1TSHRMAPT | |
| SCHEMBL6132372 | 0.83 | HDAC3 (0.53) | HDAC3HDAC8ALDH1A1CHRM4S1PR2 | |
| SCHEMBL6132282 | 0.83 | PDE4D (0.46) | HDAC3HDAC8ALDH1A1TSHRMAPT | |
| SCHEMBL6134631 | 0.82 | HDAC3 (0.50) | HDAC3HDAC8ALDH1A1SMN1; SMN2 | |
| SCHEMBL6132688 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHRMAPTSMN1; SMN2HTT | |
| SCHEMBL6134644 | 0.82 | HDAC3 (0.51) | HDAC3HDAC8ALDH1A1TSHRMAPT | |
| SCHEMBL6241221 | 0.82 | USP2 (0.46) | HDAC3HDAC8ALDH1A1TSHRMAPT | |
| SCHEMBL6235992 | 0.82 | HDAC3 (0.54) | HDAC3HDAC8CHRM4 | |
| SCHEMBL7341735 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL6134989 | 0.81 | ALDH1A1 (0.51) | HDAC3HDAC8ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | HDAC3 1534/4885HDAC8 2137/4885ALDH1A1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.